Specificity of antibodies produced against native or desialylated human immunodeficiency virus type 1 recombinant gp160
- PMID: 7679751
- PMCID: PMC237545
- DOI: 10.1128/JVI.67.3.1693-1697.1993
Specificity of antibodies produced against native or desialylated human immunodeficiency virus type 1 recombinant gp160
Abstract
In a previous report we have shown that, in contrast to antibodies produced against native or fully deglycosylated human immunodeficiency virus type 1 (HIV-1) gp160 in rabbits, antibodies raised against desialylated HIV-1 gp160 also recognize gp140 from HIV-2 at high titers. Here, we characterize the fine specificity of these cross-reactive antibodies. Inhibition assays with a panel of synthetic peptides as competitors showed that cross-reactivity to gp140 was due to antibodies that were specific for the region encompassing HIV-1 gp41 immunodominant epitope, mimicked by peptide P39 (residues 583 to 609), the latter being able to totally inhibit the formation of complexes between radiolabeled HIV-2 gp140 and antibodies elicited by desialylated HIV-1 gp160. In addition, anti-desialylated gp160 antibodies retained on a P39 affinity column still bound HIV-2 gp140. Fine mapping has enabled us to localize the cross-reactive epitope within the N-terminal extremity of the gp41 immunodominant region. Interestingly, this cross-reactive antibody population did not recognize glycosylated or totally deglycosylated simian immunodeficiency virus gp140 despite an amino acid homology with HIV-1 within this region that is comparable to that of HIV-2. This cross-reactivity between HIV-1 and HIV-2 did not correlate with cross-neutralization. These results illustrate the influence of carbohydrate moieties on the specificity of the antibodies produced and clearly indicate that such procedures may be an efficient way to raise specific immune responses that are not type specific. Moreover, this cross-reactivity might explain the double-positive reactivity observed, in some human sera, against both HIV-1 and HIV-2 envelope antigens.
Similar articles
-
Effect of sialic acid removal on the antibody response to the third variable domain of human immunodeficiency virus type-1 envelope glycoprotein.FEBS Lett. 1994 Mar 21;341(2-3):244-50. doi: 10.1016/0014-5793(94)80465-6. FEBS Lett. 1994. PMID: 8137947
-
Influence of carbohydrate moieties on the immunogenicity of human immunodeficiency virus type 1 recombinant gp160.J Virol. 1992 Apr;66(4):2473-83. doi: 10.1128/JVI.66.4.2473-2483.1992. J Virol. 1992. PMID: 1347797 Free PMC article.
-
Specificity of antipeptide antibodies produced against V2 and V3 regions of the external envelope of human immunodeficiency virus type 2.Mol Immunol. 1994 Apr;31(5):361-9. doi: 10.1016/0161-5890(94)90114-7. Mol Immunol. 1994. PMID: 8152439
-
Current approaches to vaccination against human immunodeficiency viruses.Allergol Immunopathol (Madr). 1991 Jan-Feb;19(1):11-3. Allergol Immunopathol (Madr). 1991. PMID: 1719790 Review. No abstract available.
-
How antibodies block HIV infection: paths to an AIDS vaccine.Trends Biochem Sci. 1992 May;17(5):191-6. doi: 10.1016/0968-0004(92)90265-b. Trends Biochem Sci. 1992. PMID: 1350693 Review.
Cited by
-
Resistance of native, oligomeric envelope on simian immunodeficiency virus to digestion by glycosidases.J Virol. 2000 Dec;74(23):11181-90. doi: 10.1128/jvi.74.23.11181-11190.2000. J Virol. 2000. PMID: 11070015 Free PMC article.
-
Induction of hepatitis C virus E1 envelope protein-specific immune response can be enhanced by mutation of N-glycosylation sites.J Virol. 2001 Dec;75(24):12088-97. doi: 10.1128/JVI.75.24.12088-12097.2001. J Virol. 2001. PMID: 11711599 Free PMC article.
-
Single amino acid substitution in constant region 1 or 4 of gp120 causes the phenotype of a human immunodeficiency virus type 1 variant with mutations in hypervariable regions 1 and 2 to revert.J Virol. 1996 Jan;70(1):607-11. doi: 10.1128/JVI.70.1.607-611.1996. J Virol. 1996. PMID: 8523579 Free PMC article.
-
Flow cytometric immunofluorescence assay for detection of antibodies to human immunodeficiency virus type 1 using insoluble precursor forms of recombinant polyproteins as carriers and antigens.J Clin Microbiol. 1996 Jun;34(6):1412-9. doi: 10.1128/jcm.34.6.1412-1419.1996. J Clin Microbiol. 1996. PMID: 8735090 Free PMC article.
-
Conserved Role of an N-Linked Glycan on the Surface Antigen of Human Immunodeficiency Virus Type 1 Modulating Virus Sensitivity to Broadly Neutralizing Antibodies against the Receptor and Coreceptor Binding Sites.J Virol. 2015 Oct 28;90(2):829-41. doi: 10.1128/JVI.02321-15. Print 2016 Jan 15. J Virol. 2015. PMID: 26512079 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical